1. Shexiang Tongxin dropping pill protects against isoproterenol-induced myocardial ischemia in vivo and in vitro
- Author
-
Jiaru Luo, Dancai Fan, Minzhou Zhang, Juan Yu, Jianyong Qi, Wenjun Pan, Yafang Tan, and Jiashin Wu
- Subjects
signaling pathway ,0301 basic medicine ,Traditional Chinese medicine ,Pharmacology ,Angina ,03 medical and health sciences ,0302 clinical medicine ,Intensive care ,Ca2+/calmodulin-dependent protein kinase ,Troponin I ,medicine ,rat ,Protein kinase B ,Metoprolol ,biology ,isoproterenol ,business.industry ,medicine.disease ,myocardial ischemia ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Shexiang Tongxin dropping pill ,biology.protein ,Creatine kinase ,business ,Research Paper ,medicine.drug - Abstract
// Jianyong Qi 1, 2, * , Wenjun Pan 1, 2, * , Yafang Tan 1, 2, * , Jiaru Luo 1, 2, * , Dancai Fan 1, 2 , Juan Yu 3 , Jiashin Wu 4 and Minzhou Zhang 1, 2 1 AMI Key Laboratory of Chinese Medicine in Guangzhou, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, Guangzhou 510006, China 2 Intensive Care Research Team of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, Guangzhou 510006, China 3 Animal Center, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province Hospital of Chinese Medicine, Guangzhou 510006, China 4 Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio 44272, USA * These authors have contributed equally to this work and share the first authorship Correspondence to: Minzhou Zhang, email: minzhouzhang8@163.com Keywords: myocardial ischemia; isoproterenol; signaling pathway; rat; Shexiang Tongxin dropping pill Received: July 27, 2017 Accepted: October 28, 2017 Published: November 14, 2017 ABSTRACT Shexiang Tongxin dropping pill (STDP) is a formulae of Chinese Medicine commonly used to treating angina pectoris in China. However, its mechanism of action is still yet unclear. This study investigated the roles of STDP on myocardial ischemia injury. We constructed a rat model of myocardial injury (isoproterenol subcutaneous injection, i.h, 85 mg/kg/day for 2 days), and compared among 4 groups: CON (control), ISO (ischemic injury model), MET (metoprolol), and STDP. Serum contents of Troponin I (cTnI), creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), alpha-hydroxybutyric dehydrogenase (α-HBD), and Aspartate Aminotransferase were detected and five STDP doses (1, 10, 100, 1000 and 10000 mg/kg/day) were chosen to obtain a dose-response curve. Western-blot was used to detect phosphorylations of extracellular signal-regulated kinase 1/2 (ERK1/2), protein kinase B (AKT), and camodulin kinase II (CamkII). Furthermore, an ERK1/2 inhibitor PD98059, a phosphatidylinositol-3-kinase inhibitor, LY294002, and a CamKII inhibitor, KN-93 were administered i.h. Results: cTnI, CK, CK-MB, α-HBD, and LDH were significantly lower in STDP than ISO ( P
- Published
- 2017
- Full Text
- View/download PDF